Esperion Therapeutics, Inc. (ESPR)
- GlobeNewswire
Esperion Provides Preliminary Fourth Quarter 2021 Financial Results and CLEAR Outcomes Program Update
– Unprecedented CLEAR Outcomes Trial Remains On-Track for Complete Major Adverse Cardiac Events (MACE) Accumulation in 2H 2022; Achieved 85% MACE Accumulation in December – – Fourth-quarter 2021 U.S. Net Product Revenue Estimated Between $12.0 to $12.5 Million – – Company Reiterates Full-Year 2022 Operating Expense Guidance of $220 to $240 Million – ANN ARBOR, Mich., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced preliminary, unaudited fourth-quarter 2021 financial res
- GlobeNewswire
Esperion to Participate in Upcoming Virtual J.P. Morgan 40th Annual Healthcare Conference
ANN ARBOR, Mich., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that President and Chief Executive Officer, Sheldon Koenig, will present at the upcoming virtual J.P. Morgan 40th Annual Healthcare Conference on Thursday, January 13, 2022 at 10:30 a.m. Eastern Time. Event:J.P. Morgan 40th Annual Healthcare ConferenceDate:Thursday, January 13, 2022Format:Presentation and 1:1 MeetingsTime:10:30 a.m. ET Live audio webcasts of these events can be accessed on the investor re
- Simply Wall St.
What Type Of Shareholders Own The Most Number of Esperion Therapeutics, Inc. (NASDAQ:ESPR) Shares?
Every investor in Esperion Therapeutics, Inc. ( NASDAQ:ESPR ) should be aware of the most powerful shareholder groups...
